US · EVGN · BIOTECHNOLOGY
Evogene Ltd. (EVGN) intrinsic value and stock valuation
$0.32as of 2026-11-21 · Mkt cap 5.44M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Evogene Ltd. DCF and intrinsic value
InvestorsCraft values EVGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EVGN’s statements →
Evogene Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $930K |
| Operating income | -$-14.03M | -$-18.8M | -$-22.23M | -$-26.94M | -$-30.95M |
| Net income | -$-8.48M | -$-16.48M | -$-23.88M | -$-26.64M | -$-27.79M |
| EPSd | -$-1.08M | -$-2.89M | -$-5.23M | -$-6.47M | -$-677.64K |
| Operating cash flow | -$-13.5M | -$-19.7M | -$-21.58M | -$-23.68M | -$-24.84M |
| Capital expenditure | -$-140K | -$-630K | -$-790K | -$-1.17M | -$-720K |
| Free cash flow | -$-13.64M | -$-20.33M | -$-22.36M | -$-24.85M | -$-25.56M |
| Total assets | $20.1M | $39.9M | $51.1M | $56.1M | $76.3M |
| Total debt | $2.2M | $12.9M | $11.5M | $11.9M | $2.67M |
| Net debt | -$-10.76M | -$-2.43M | -$-9.27M | -$-17.05M | -$-29.66M |
| Total equity | $12M | $14.8M | $28.7M | $34.8M | $63.4M |
| Cash and short-term investments | $13M | $15.3M | $31.1M | $35.4M | $53.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.85M | $5.58M | $2.98M | $1.68M | $930K |
| Cost of revenue | $4.09M | $2.38M | $1.49M | $910K | $770K |
| Gross profit | -$-240K | $3.2M | $1.49M | $770K | $160K |
| Research and development expenses | $7.99M | $12.5M | $16.2M | $20.8M | $21.1M |
| Selling, general and administrative expenses | $5.76M | $8.98M | $7.53M | $10.4M | $9.99M |
| Other expenses | $40K | $510K | $0.00 | -$-3.5M | $0.00 |
| Operating expenses | $13.8M | $22M | $23.7M | $27.7M | $31.1M |
| Cost and expenses | $17.9M | $24.4M | $25.2M | $28.6M | $31.9M |
| Interest income | $2.47M | $960K | $1.25M | $180K | $290K |
| Interest expense | $1.89M | $120K | $170K | $240K | $400K |
| Depreciation and amortization | $1.14M | $1.38M | $1.3M | $2.58M | $2.23M |
| Ebitda | -$-12.2M | -$-13.36M | -$-20.53M | -$-27.01M | -$-27.88M |
| Operating income | -$-14.03M | -$-18.8M | -$-22.23M | -$-26.94M | -$-30.95M |
| Total other income/expenses, net | $540K | $4M | $280K | -$-2.81M | $520K |
| Income before tax | -$-13.5M | -$-14.81M | -$-21.95M | -$-29.75M | -$-30.43M |
| Income tax expense | $0.00 | $10K | $20K | $90K | $10K |
| Net income | -$-8.48M | -$-16.48M | -$-23.88M | -$-26.64M | -$-27.79M |
| Weighted average shares outstanding | $7.87M | $5.7M | $4.57M | $4.12M | $41M |
| Weighted average diluted shares outstanding | $7.87M | $5.7M | $4.57M | $4.12M | $41M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $13M | $15.3M | $31.1M | $35.4M | $53.9M |
| Net receivables | $1.38M | $1.49M | $800K | $800K | $1.17M |
| Inventory | $210K | $1.82M | $80K | $570K | $90K |
| Total current assets | $15.6M | $21.6M | $34.5M | $37.8M | $56.9M |
| Property, plant and equipment, net | $2.64M | $4.25M | $3.44M | $4.07M | $4.18M |
| Goodwill and intangible assets | $0.00 | $12.2M | $13.2M | $14.1M | $15.2M |
| Long-term investments | $40K | $80K | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $4.42M | $18.3M | $16.6M | $18.4M | $19.4M |
| Total assets | $20.1M | $39.9M | $51.1M | $56.1M | $76.3M |
| Accounts payable | $640K | $1.23M | $1.78M | $1.04M | $1.46M |
| Short-term debt | $720K | $11M | $1.71M | $1.77M | $1.95M |
| Deferred revenue | $70K | $680K | $750K | $100K | $260K |
| Total current liabilities | $3.44M | $18.7M | $6.94M | $5.62M | $6.88M |
| Long-term debt | $1.48M | $1.91M | $10.7M | $11.1M | $1.7M |
| Deferred revenue, non-current | $3.07M | $4.33M | $4.43M | $4.67M | $4.31M |
| Total non-current liabilities | $4.63M | $6.33M | $15.5M | $15.7M | $6M |
| Capital lease obligations | $2.2M | $2.5M | $1.14M | $1.82M | $2.67M |
| Total liabilities | $8.07M | $25M | $22.4M | $21.3M | $12.9M |
| Common stock | $490K | $360K | $290K | $230K | $230K |
| Retained earnings | -$-282.56M | -$-274.07M | -$-257.59M | -$-233.71M | -$-207.07M |
| Accumulated other comprehensive income (loss) | $0.00 | $272.3M | $269.4M | $261.4M | $260.5M |
| Total equity | $12M | $14.8M | $28.7M | $34.8M | $63.4M |
| Total investments | $40K | $90K | $10.3M | $6.38M | $21.5M |
| Total debt | $2.2M | $12.9M | $11.5M | $11.9M | $2.67M |
| Net debt | -$-10.76M | -$-2.43M | -$-9.27M | -$-17.05M | -$-29.66M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-14.16M | -$-18.05M | -$-25.95M | -$-29.84M | -$-30.45M |
| Depreciation and amortization | $1.14M | $2.5M | $2.61M | $2.58M | $2.23M |
| Stock-based compensation | $650K | $1.79M | $1.88M | $1.19M | $2.61M |
| Change in working capital | -$-1.25M | -$-3.31M | -$-400K | -$-770K | $1.66M |
| Accounts receivable | $1.71M | $190K | -$-1.45M | -$-70K | -$-60K |
| Inventory | -$-1.02M | -$-1.74M | $490K | -$-470K | -$-90K |
| Accounts payable | -$-260K | -$-600K | $740K | -$-470K | $620K |
| Net cash provided by operating activities | -$-13.5M | -$-19.7M | -$-21.58M | -$-23.68M | -$-24.84M |
| Investments in property, plant and equipment | -$-140K | -$-630K | -$-790K | -$-1.17M | -$-720K |
| Acquisitions, net | $80K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $17.7M | $9.62M | -$-4.54M | $13.3M | -$-20.44M |
| Common stock issued | $4.28M | $120K | $8.45M | $20K | $29.6M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-6.6M | $4.66M | $18.2M | $9.34M | $30.3M |
| Net change in cash | -$-2.35M | -$-5.47M | -$-8.21M | -$-3.35M | -$-13.9M |
| Cash at end of period | $13M | $15.3M | $20.8M | $29M | $32.3M |
| Operating cash flow | -$-13.5M | -$-19.7M | -$-21.58M | -$-23.68M | -$-24.84M |
| Capital expenditure | -$-140K | -$-630K | -$-790K | -$-1.17M | -$-720K |
| Free cash flow | -$-13.64M | -$-20.33M | -$-22.36M | -$-24.85M | -$-25.56M |
Line items
Line items
Line items
About Evogene Ltd.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
- CEO
- Ofer Haviv
- Employees
- 52
- Beta
- 0.78
Explore
Frequently asked questions
What is the intrinsic value of Evogene Ltd. (EVGN)?
InvestorsCraft does not currently publish an intrinsic value for EVGN. How the IC value is calculated.
Is EVGN undervalued?
InvestorsCraft does not publish an undervaluation signal for EVGN at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.